Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multicenter, Randomized, Open-label Study to Investigate the Safety and Efficacy of Pegfilgrastim (Neulasta®) in Patients With Alcoholic Hepatitis

NCT02776059 is registered in ClinicalTrials.gov with Timothy Morgan, MD as lead sponsor.

NCT NCT02776059
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02776059 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multicenter, Randomized, Open-label Study to Investigate the Safety and Efficacy of Pegfilgrastim (Neulasta®) in Patients With Alcoholic Hepatitis
Lead sponsor
Timothy Morgan, MD
Phase
Phase 2
Overall status
Completed
Start date
January 21, 2017
Completion date
March 31, 2021
Enrollment
34 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

alcoholic hepatitis